DOI: http://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20195299

Evaluation of omalizumab at certain time intervals in patients with chronic spontaneous idiopathic urticaria

Ömer Kutlu, Engin Karaarslan, Nermin Karaosmanoğlu, Hatice Meral Ekşioğlu

Abstract


Background: In this study, we aimed to evaluate the response of patient treated with omalizumab at certain time intervals through 6 months with pruritus visual analog scale, urticaria activity score and quality of life indexes.

Methods: The study was performed on ten patients diagnosed with chronic idiopathic spontaneous urticaria. The disease was assessed by the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) and Dermatology Life Quality Index (DLQI) for every 2 weeks while was assessed by Urticaria Activity Score (UAS-7) and Pruritus Visual Analog Scale (PVAS) for once a week during the 6-month treatment period. Statistical significance was evaluated using the Mann-Whitney U test in SPSS 20.  

Results: Pre-treatment values of the DLQI, CU-Q2oL, UAS-7, and PVAS was statistically higher than post-treatment values of these indexes (p<0.05). The mean DLQI/ CU-Q2oL value of the patients before treatment was 17±6.09/ 52.87±22.07 while it was 19.4±16.36 at the end of 2nd-week post-injection per month, and was 21.85±16.56 at the end of 4nd-week post-injection per month during 6-months following. Statistically, PVAS score at the fourth week was higher than 2nd and 4th week (p<0.042, p<0.007).

Conclusions: In this study, it was detected that omalizumab had a significant effect on DLQI, CU-Q2oL, UAS-7, PVAS scores in CISU. It can be concluded that significant increase of PVAS score at 4th week compared to scores at 2nd and 3rd week may necessitate the use of omalizumab combined with antihistamines at 4th week of the treatment.


Keywords


Life quality, Omalizumab, Pruritus visual analog scale, Urticaria

Full Text:

PDF

References


Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-81.

Kaplan AP. Chronic spontaneous urticaria: pathogenesis and treatment considerations. Allergy Asthma Immunol Res. 2017;9(6):477-82.

Kavati A, Zhdanava M, Ortiz B, LeCocg J, Schiffman B, Pilon D, et al. Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allerg Asthma Proc. 2019:40(5):321-8.

Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Cl, 2005;5(5):403-7.

Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638-49.

Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol. 2011;29:209.

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018:73(7):1393-414.

Langner M, Maibach H. Pruritus measurement and treatment. Clin Experimen Dermatol. 2009;34(3):285-8.

Kocatürk E, Weller K, Martus P, Aktas S, Kavala M, Sarigul S, et al. Turkish version of the chronic urticaria quality of life questionnaire: cultural adaptation, assessment of reliability and validity. Acta Derm Venereol. 2012;92(4):419-25.

Ertaş R, Ozyurt K, Atasoy, Hawro T, Maurer M. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy. 2018;73(3):705-12.

Büyüköztürk S, Gelincik A, Demirtürk M, Kocaturk E, Colakoğlu B, Dal M. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol. 2012;39(5):439-42.

Janssens N, Maurer M, Khalil S, Balp MM, Rosen K. Omalizumab Improves Quality of Life (QoL) in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): A Post-Hoc Analysis of Percent Change from Baseline to Week 12. J Allergy Clin Immunol. 2015;135(2):AB132.

Staubach P, Metz M, Chapman-Rothe N, Sieder C, Brautigam M, Maurer M, et al. Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data. Allergy. 2018;73(3):576-84.

Bulur I, Bulbul Baskan E, Ozdemir M, Balevi A, Kocatürk E, Altunay I, et al. The efficacy and safety of omalizumab in refractory chronic spontaneous urticaria: real-life experience in Turkey. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(3):121-6.

Carrillo DC, Borges MS, Garcia E, Egae E, Serrano CD. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review. World Allergy Organ J. 2014;7(1):72.

Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-73.

Maurer M, Rosén K, Hsieh HJ,Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. New Engl J Med. 2013;368(10):924-35.

Saini SS, Bindslev- Jensen C, Maurer M, Grob J, Bülbül Başkan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67-75.

Uysal P, Eller E, Mortz CG, Bindsley-Jensen C. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized. J Allergy and Clin Immunol. 2011;133(3):914-15.